Feedback
Settings

Settings

Goto Application

7,398 results
Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 740
1.2526431COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
CA - 03.03.2005
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No 2526431 Applicant WYETH HOLDINGS CORPORATION Inventor SIBER, GEORGE R.
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

2.WO/2005/011649METHODS OF TREATING SEVERE ACUTE RESPIRATORY SYNDROME VIRUS INFECTIONS
WO - 10.02.2005
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
 Appl.No PCT/US2004/015536 Applicant VANDERBILT UNIVERSITY Inventor DENISON, Mark
The present invention provides methods for inhibiting severe acute respiratory syndrome (SARS) virus infections. Specifically, cysteine proteinase inhibitors are proposed as therapeutics for SARS, potentially used in combination with interferons.
3.WO/2019/135003PEPTIDES HAVING PROTEASE ACTIVITY FOR USE IN THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION
WO - 11.07.2019
Int.Class A61K 38/48
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
 Appl.No PCT/EP2019/050266 Applicant ENZYMATICA AB Inventor GUÐMUNDSDÓTTIR, Ágústa
The present invention provides a polypeptide having protease activity for use in the treatment or prevention of coronavirus infection in a mammal. In particular, the invention relates to treatment or prevention of a coronavirus infection in a human, using trypsins.
4.WO/2004/091653INTERFERON BETA IN SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
WO - 28.10.2004
Int.Class A61K 31/7056
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
7056containing five-membered rings with nitrogen as a ring hetero atom
 Appl.No PCT/EP2004/050456 Applicant ARES TRADING S.A. Inventor DE LUCA, Giampiero
The use of an interferon (IFN) for the manufacture of a medicament useful for treatment and/or prevention of Severe Acute Respiratory Syndrome (SARS) is described in the present invention.
5.20200352986METHODS AND COMPOSITIONS FOR ALLEVIATING RESPIRATORY DYSFUNCTION
US - 12.11.2020
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
 Appl.No 16936036 Applicant Shawn J. Green Inventor Shawn J. Green

Compositions, methods of manufacturing compositions, methods of protecting against respiratory problems including coronavirus and coronavirus-associated severe acute respiratory syndrome (SARS) in humans and animals, are provided. Compositions comprising inorganic nitrate used for improving nitric oxide levels, improving health and/or reducing symptoms of SARS are provided. The compositions and methods are applicable for subjects experiencing SARS, and for protecting non-infected subjects against SARS. Compositions and methods for improving nitric oxide levels in a subject disclosed herein comprise administration of compositions comprising inorganic nitrate such as potassium nitrate or sodium nitrate optionally combined with ascorbate.

6.WO/2004/100980INTERFERON FOR TREATING OR PREVENTING A CORONAVIRAL INFECTION
WO - 25.11.2004
Int.Class A61K 31/7056
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
7056containing five-membered rings with nitrogen as a ring hetero atom
 Appl.No PCT/GB2004/002183 Applicant VIRAGEN, INC. Inventor JERVIS, Karen, Elizabeth
The present invention provides a composition and method for use in the prevention or treatment of a coronaviral infection and in particular, the human coronavirus infection termed severe acute respiratory syndrome (SARS) coronavirus (SARS-HCoV). A method of treating a coronaviral infection is provided through the administration of interferon, further the use of interferons in the treatment of a coronaviral infection is also provided. Preferred forms of interferon for use in the invention are multi-subtype interferon products such as multi-subtype, human alpha-interferon derived from white blood cells commercially available as Multiferon.
7.WO/2004/108122GLYCYRRHIZIN OR DERIVATIVES THEREOF FOR TREATING OR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
WO - 16.12.2004
Int.Class A61K 31/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
04Nitro compounds
 Appl.No PCT/IB2004/002393 Applicant JOHANN WOLFGANG GOETHE UNIVERSITY Inventor CINATL, Jindrich
The invention provides methods for preventing, treating, managing or ameliorating viral infections, in particular, Severe Acute Respiratory Syndrome (SARS). More specifically, the invention provides methods for preventing, treating, managing or ameliorating a SARS-associated coronavirus or one or more symptoms thereof by administering Glycyrrhizin and/or derivatives thereof The invention also provides methods for preventing, treating, managing or ameliorating a SARS-associated coronavirus or one or more symptoms thereof by administering Glycyrrhizin and/or a derivative thereof in combination with a prophylactic or therapeutic agent other than Glycyrrhizin or a derivative thereof.
8.20090137818Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
US - 28.05.2009
Int.Class A61K 31/422
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
422not condensed and containing further heterocyclic rings
 Appl.No 11273270 Applicant Universitat zu Luebeck Inventor Hilgenfeld Rolf

The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.

9.WO/2004/093888CHARGED POLYSACCHARIDES RESISTANT TO LYSOSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE AND THEIR USE TO TREAT OR PREVENT INFECTION BY CORONAVIRUSES
WO - 04.11.2004
Int.Class A61K 31/737
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
 Appl.No PCT/AU2004/000518 Applicant MONASH UNIVERSITY Inventor COMPER, Wayne, D.
This invention relates to methods for treating, preventing or managing coronavirus infections in mammals using sulfated polysaccharides. More particularly, this invention relates to methods of treating, preventing or managing infection by coronaviruses, particularly viral infections leading to or causing diseases such as the newly discovered Severe Acute Respiratory Syndrome (“SARS”). The invention involves the use of sulfated polysaccharides which are abundant, non-toxic and inexpensive and which are potent antivirals in vivo.
10.20050004071Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
US - 06.01.2005
Int.Class A61K 31/737
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
 Appl.No 10827757 Applicant Inventor Comper Wayne D.

This invention relates to methods for treating, preventing or managing coronavirus infections in mammals using sulfated polysaccharides. More particularly, this invention relates to methods of treating, preventing or managing infection by coronaviruses, particularly viral infections leading to or causing diseases such as the newly discovered Severe Acute Respiratory Syndrome (“SARS”). The invention involves the use of sulfated polysaccharides which are abundant, non-toxic and inexpensive and which are potent antivirals in vivo.

# -